TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Lyka Labs Ltd.
LYKALABS Updated about 16 hours ago

Lyka Labs Ltd. Share Price

NSE closing price and which mutual funds hold this stock

TopFund Score: 42/100 · Weak See breakdown ↓

Daily NSE closing prices — this stock isn't in the live-tracked universe yet.

NSE Close — 25 Sep 2026

₹85.85

Change

-1.15 (-1.32%)

Open

₹86.5

Prev. Close

₹87.0

Day High

₹86.5

Day Low

₹85.85

Volume Analysis

Traded

3,962

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (3)

  • •Low return on equity (-10.2%)
  • •Below-average fundamentals quality score (42/100)
  • •Low operating margin (-2.0%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹86.94 ₹86.72 ₹86.29 ₹86.07 ₹85.64 ₹85.42 ₹84.99
Fibonacci ₹86.72 ₹86.47 ₹86.32 ₹86.07 ₹85.82 ₹85.67 ₹85.42
Camarilla ₹86.03 ₹85.97 ₹85.91 ₹86.07 ₹85.79 ₹85.73 ₹85.67

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+12.09%

1 Week

+1.0%

1 Month

+14.77%

3 Months

+16.09%

6 Months

+67.77%

1 Year

-9.49%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹31.2

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

-9.07%

Net margin -6.52% × asset turnover 0.74x × equity multiplier 1.88x

Company Overview

Sector

Healthcare

Market Cap

₹310 Cr

ROE

-10.2%

Book Value

₹25.9

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.

TopFund Analysis

Lyka Labs Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 42/100. The strongest factor is Financial Strength (86/100), while Liquidity (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (-10.2%); below-average fundamentals quality score (42/100).

TopFund Score — Fundamentals Quality

42/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

86

Growth

48

Valuation

33

Cash Flow

11

Corporate Governance

66

Momentum

68

Institutional Ownership

30

Business Quality

20

Risk & Volatility

49

Liquidity

0

From Screener.in

  • +Company's working capital requirements have reduced from 32.4 days to 22.7 days
  • −Stock is trading at 3.32 times its book value
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of 8.29% over past five years.
  • −Company has a low return on equity of -2.04% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Closure of Trading Window 24 Sep

Trading window closed from 1 October 2026 until 48 hours after Q2 FY2026-27 results.

Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Aug 12 Aug
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 11 Aug 11 Aug
Revised Press Release On Unaudited Financial Results For The Q1 June, 2026 11 Aug

Lyka Labs revised Q1 FY27 unaudited results; net profit rose 159.06% to Rs. 210.03 lakhs.

Shareholder Meeting / Postal Ballot-Outcome of AGM 10 Aug

47th AGM held on 10 Aug 2026 via VC/OAVM; members considered five resolutions, including IPCA-related transactions.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 23 28 33 28 30 41 34 33 33 37 31 28 42
Expenses + 20 24 26 26 26 36 29 29 29 39 29 34 38
Operating Profit 3 4 7 2 4 5 5 4 4 -3 2 -6 5
OPM % 11.54% 14.9% 21.1% 7.27% 12.32% 12.03% 15.36% 12.2% 11.14% -6.93% 5.37% -23.01% 10.75%
Other Income + 0 0 1 0 1 0 1 1 1 1 1 1 0
Interest 1 1 1 1 1 1 1 0 1 1 1 1 1
Depreciation 3 4 3 3 2 2 2 1 2 2 2 2 2
Profit before tax -2 -1 3 -2 2 3 4 3 1 -4 0 -9 2
Tax % 7.22% -22.78% 38.6% 28.22% 30.65% 28.36% 24.3% 32.89% 26.67% -26.65% -6.25% -6.06% -5.13%
Net Profit + -2 0 2 -2 1 2 3 2 1 -3 0 -8 2
EPS in Rs -1 0 1 -1 0 1 1 1 0 -1 0 -2 1
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Jun 2015 Mar 2016 9m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 166 130 110 60 71 61 86 194 93 111 138 128 138
Expenses + 139 110 87 63 73 65 67 93 76 95 121 132 141
Operating Profit 28 20 23 -4 -2 -4 20 101 17 16 18 -3 -3
OPM % 17.0% 16.0% 21.0% -6.0% -2.7% -6.0% 23.0% 52.0% 18.0% 14.0% 13.0% -2.7% -2.0%
Other Income + 4 8 -2 4 1 -30 0 -4 -4 1 2 4 3
Interest 24 15 19 10 7 20 26 20 12 5 2 3 3
Depreciation 11 9 10 11 7 8 8 17 14 13 7 8 8
Profit before tax -3 4 -8 -20 -15 -62 -14 59 -13 -1 11 -12 -11
Tax % 31.0% -5.0% -19.0% -5.0% -59.0% 1.0% -29.0% 35.0% 0.0% 182.0% 29.0% -11.0% —
Net Profit + -5 4 -7 -19 -6 -63 -10 38 -13 -3 8 -10 -9
EPS in Rs -2 2 -3 -6 -2 -21 -4 14 -4 -1 2 -3 -3
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 20 22 16 21 15 -43 -54 -15 15 35 69 57
Borrowings + 137 121 126 113 96 141 163 130 75 59 39 49
Other Liabilities + 100 77 88 67 76 73 52 42 31 30 32 33
Total Liabilities 279 242 252 229 216 200 190 186 152 157 176 175
Fixed Assets + 122 104 133 116 108 105 98 94 68 58 85 87
CWIP 27 30 24 28 31 28 26 18 16 23 1 2
Investments 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 130 107 94 85 77 68 66 74 67 76 90 86
Total Assets 279 242 252 229 216 200 190 186 152 157 176 175
Equity Capital 22 22 22 28 28 29 29 29 31 33 36 36

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 27 12 31 11 27 5 9 79 9 2 2 5
Cash from Investing Activity + 37 17 -13 -3 -4 0 0 -6 7 -9 -12 -9
Cash from Financing Activity + -60 -30 -19 -10 -23 3 -12 -63 -22 2 5 4
Net Cash Flow 4 -1 0 -3 -1 9 -3 10 -5 -6 -5 0
CFO/OP 97 60 143 -318 -1,462 -131 49 79 52 21 28 -159
Free Cash Flow 55 28 18 7 23 4 8 72 15 -7 -10 -6

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 54.81% → 58.45%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 44.61% 44.41% 44.21% 40.99% 41.08% 41.07% 40.93% 41.02% 40.99% 40.99% 40.89% 40.73%
Promoters 54.81% 54.81% 54.81% 58.11% 58.11% 58.11% 58.16% 58.16% 58.16% 58.16% 58.16% 58.45%
FII 0.18% 0.17% 0.17% 0.15% 0.15% 0.15% 0.24% 0.16% 0.17% 0.17% 0.29% 0.17%
DII 0.41% 0.62% 0.81% 0.75% 0.66% 0.66% 0.66% 0.66% 0.66% 0.66% 0.66% 0.66%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Lyka Labs Ltd. (this stock) 310 — 3.31 -10.2%
Ambalal Sarabhai Ent L 316 22.2 2.0 12.4%
Nureca Limited 335 77.3 1.86 1.12%
Bilcare Ltd. 257 12.9 1.3 1.39%
Qms Medical Allied S Ltd 380 35.4 3.65 10.4%
Take Limited 229 38.9 7.38 16.5%
Nectar Lifesciences Ltd. 211 — 0.36 -31.3%

Which Mutual Funds Hold Lyka Labs Ltd.?

Frequently Asked Questions about Lyka Labs Ltd.

Community Sentiment

What are other investors saying about Lyka Labs Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.